Blackrock Neurotech is the leading provider of implantable brain-computer interface (BCI) technology, headquartered in Salt Lake City, Utah. Founded in 2008 as a spinout from the [University of Utah](/institutions/university-of-utah), the company has developed the most clinically validated invasive BCI technology in the world through its flagship Utah Array.
The company holds a unique position as the only provider of FDA-approved implantable neural arrays, with over 15 years of continuous clinical data from more than 50 patient implantations. This regulatory moat, combined with an extensive patent portfolio and established manufacturing capabilities, has made Blackrock the dominant player in the clinical-grade invasive BCI market.
Blackrock raised over $120 million in total funding before transitioning to commercial stage with its FDA-approved MoveAgain BCI system in 2023. The company employs approximately 150 people and is pursuing an aggressive product roadmap including next-generation Neuralace technology with 10,000+ electrodes.
Key Facts
| Attribute | Details | |-----------|---------| | Founded | 2008 | | Headquarters | Salt Lake City, Utah | | CEO | Marcus Gerhardt | | Total Funding | $120M+ | | Employees | ~150 | | FDA Approvals | 2 (Utah Array, MoveAgain BCI) | | Clinical Patients | 50+ | | Market Share | ~70% (invasive BCI) |
Technology Platform
Utah Array
The Utah Array is Blackrock's flagship product and the gold standard for chronic neural interface technology:
...
Overview
Blackrock Neurotech is the leading provider of implantable brain-computer interface (BCI) technology, headquartered in Salt Lake City, Utah. Founded in 2008 as a spinout from the [University of Utah](/institutions/university-of-utah), the company has developed the most clinically validated invasive BCI technology in the world through its flagship Utah Array.
The company holds a unique position as the only provider of FDA-approved implantable neural arrays, with over 15 years of continuous clinical data from more than 50 patient implantations. This regulatory moat, combined with an extensive patent portfolio and established manufacturing capabilities, has made Blackrock the dominant player in the clinical-grade invasive BCI market.
Blackrock raised over $120 million in total funding before transitioning to commercial stage with its FDA-approved MoveAgain BCI system in 2023. The company employs approximately 150 people and is pursuing an aggressive product roadmap including next-generation Neuralace technology with 10,000+ electrodes.
Key Facts
| Attribute | Details | |-----------|---------| | Founded | 2008 | | Headquarters | Salt Lake City, Utah | | CEO | Marcus Gerhardt | | Total Funding | $120M+ | | Employees | ~150 | | FDA Approvals | 2 (Utah Array, MoveAgain BCI) | | Clinical Patients | 50+ | | Market Share | ~70% (invasive BCI) |
Technology Platform
Utah Array
The Utah Array is Blackrock's flagship product and the gold standard for chronic neural interface technology:
Electrode Count: 100-128 electrodes per array
Clinical History: 15+ years of human implantation data
Regulatory Status: FDA Approved for clinical neural recording
Applications: Motor prosthesis control, communication devices, neural monitoring
MoveAgain BCI
The MoveAgain BCI received FDA approval in 2023 as the first commercial BCI system for patients with paralysis:
Enables wireless control of computers and devices
Clinically validated in patients with tetraplegia
First FDA-approved therapeutic BCI product
Neuralace (Development)
Next-generation ultra-high-density array:
10,000+ electrodes on flexible conformal substrate
Wireless data transmission
Development stage, expected launch 2026-2027
Therapeutic Applications
Amyotrophic Lateral Sclerosis (ALS): Communication devices for locked-in syndrome patients
Spinal Cord Injury: Motor restoration for quadriplegia